Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Pharma
Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025
Pfizer is pulling the trigger on the full transition to Vyndamax as Vyndaqel is expected to lose patent protection in 2028.
Angus Liu
Aug 29, 2025 10:40am
Alnylam's Amvuttra off to promising start in ATTR-CM
May 1, 2025 11:46am
BMS' Camzyos falls short in bid to widen eligible patient pool
Apr 15, 2025 11:42am
Alnylam's Amvuttra wins key cardiomyopathy FDA nod
Mar 20, 2025 7:40pm
JPM25: BridgeBio's cardiomyopathy drug is off to a roaring start
Jan 13, 2025 9:40pm
Look out, Pfizer: BridgeBio gains 'best-case' FDA nod for Attruby
Nov 25, 2024 7:59am
